

Fri, Mar 2, 2007 2:34 PM

**Subject: IRB Approval of Continuing Review**  
**Date: Wednesday, February 28, 2007 11:12 PM**  
**From: irb <irb@umn.edu>**  
**To: folso001 folso001@umn.edu**  
**Conversation: IRB Approval of Continuing Review**

3/2/07 Emailed to  
C. Jennings  
D. Bild  
N. Dernard ✓  
L...

The IRB: Human Subjects Committee renewed its approval of the referenced study listed below:

Study Number: 9805M00034

3/2/07 Mailed to  
Sandy Tarangji (Hett)  
at JHU

Principal Investigator: Aaron Folsom

Expiration Date: 02/21/2008

Approval Date: 02/22/2007

Title(s):

Multi-Ethnic Study of Atherosclerosis (MESA)

Subclinical Cardiovascular Disease Study: Field Center

Regional Dysfunction by MRI in Incidence Heart Function

Aortic Calcium: Epidemiology and Progression

MESA Occupational Coding Substudy - Minnesota

This e-mail confirmation is your official University of Minnesota RSPP notification of continuing review approval. You will not receive a hard copy or letter.

This secure electronic notification between password protected authentications has been deemed by the University of Minnesota to constitute a legal signature.

You may go to the View Completed section of <http://eresearch.umn.edu/> to view or print your continuing review submission.

For grant certification purposes you will need this date and the Assurance of Compliance number, which is FWA00000312 (Fairview Health Systems Research FWA00000325, Gillette Childrens Specialty Healthcare FWA00004003). Approval will expire one year from that date. You will receive a report form two months before the expiration date.

In the event that you submitted a consent document with the continuing review form, it has also been reviewed and approved. If you provided a summary of subjects' experience to include non-UPIRSTSO events, these are hereby acknowledged.

As Principal Investigator of this project, you are required by federal regulations to inform the IRB of any proposed changes in your research that will affect human subjects. Changes should not be initiated until written IRB approval is received. Unanticipated problems and adverse events should be reported to the IRB as they occur. Research projects are subject to continuing review.

If you have any questions, please call the IRB office at (612) 626-5654.

The IRB wishes you continuing success with your research.